Recombinant Peptide to Agonize PTH-R for Post Menopausal Osteoporosis is under clinical development by Enteris BioPharma and currently in Phase II for Post Menopausal Osteoporosis. According to GlobalData, Phase II drugs for Post Menopausal Osteoporosis have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Recombinant Peptide to Agonize PTH-R for Post Menopausal Osteoporosis’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Recombinant Peptide to Agonize PTH-R for Post Menopausal Osteoporosis overview
PTH analog is under development for treatment of post menopausal osteoporosis. Parathyroid hormone (PTH) is administered orally. The drug candidate is developed by using peptelligence technology.
Enteris BioPharma overview
Enteris BioPharma (Enteris) operates as a biotechnology company. It specializes in oral peptide drug delivery technology for the treatment of patients with postmenopausal osteoporosis. The company technology comprises peptelligence and properma. Its peptelligence improves oral bioavailability through a smart combination of pH-lowering, charge dispersal, membrane wetting, and solubilizing agents in a highly scalable solid oral dosage form without making physicochemical modifications to the API. Enteris Properma improve solubility and permeability of small molecules which utilizes an enteric coating surrounding a tablet core containing the API with solubilizing agents. Enteris is headquartered in Boonton, New Jersey, the US.
For a complete picture of Recombinant Peptide to Agonize PTH-R for Post Menopausal Osteoporosis’s drug-specific PTSR and LoA scores, buy the report here.